Relay Therapeutics
Drug Discovery · Biotechnology

Relay Therapeutics: Products & infrastructure

Relay Therapeutics has 5 clinical trials on record, 4 under way.

Data updated Nov 22, 2026 · Back to the company report

Products

Relay Therapeutics has 5 clinical trials on record, 4 under way.

5clinical trials
4trials under way
1in phase 3
2EU trials (CTIS)
EU clinical trialsthe trials it sponsors, per the EU's CTIS register
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib +…
Therapeutic confirmatory (Phase III) · PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gr… · Hungary, Spain, Italy, Belgium, Netherlands, Aust…
Nov 2025
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Sp…
Therapeutic exploratory (Phase II) · PIK3CA Related Overgrowth Spectrum and Malformations Driven… · Belgium, Spain, Italy, France, Germany, Ireland, …
May 2025
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
phase 2 · under way · 180 participants · Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors; NRAS Mutation…
Mar 2026
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic P…
phase 3 · under way · 540 participants · PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor;…
Aug 2025
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Sp…
phase 2 · under way · 277 participants · PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Ma…
Jun 2025
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
phase 1 · completed · 41 participants · PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer
Mar 2023
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid T…
phase 1 · under way · 930 participants · PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer
Dec 2021
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.